Add BrightSurf on Google Email

Science News for March 25, 2023


Ammonia: Efficient hydrogen carrier and green steel enabler

Researchers at Max Planck Institute developed an ammonia-based direct reduction process to produce sustainable iron and steel, overcoming logistics and energetic disadvantages of hydrogen. The process yields the same metallization degree as hydrogen-based reduction while forming nitrides that protect the sponge iron from corrosion.

SourceMax-Planck-Gesellschaft·JournalAdvanced Science·TypeExperimental study·DateMar 25, 2023

The utilization of atezolizumab as a primer for chemoradiation results in promising immune system alterations for women with locally advanced cervical cancer

The NRG-GY017 trial found that atezolizumab improved 2-year disease-free survival rates (79% vs. 59%) and pathologically complete or partial responses (69% vs. 40%) for patients with locally advanced cervical cancer. The study also showed a favorable immune response, including positive PD-L1 scoring and T-cell receptor clonal expansion.

The addition of gemcitabine with cisplatin and intensity-modulated radiation therapy improves outcomes for women with locally advanced vulvar cancer

Women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy exhibited increased rates of pathologic complete responses. The study found improved survival and response outcomes for this population, while minimizing toxicity.

The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer (LGSOC) (GO

A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateMar 25, 2023